{"prompt": "['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 9 of 61', 'Medtronic', '3. Synopsis', 'Title', 'InterStim Amplitude Study', 'Clinical Study Type', 'Post-Market, On-Label', 'Product Name', 'InterStim II (Model 3058) and InterStim Quadripolar Lead Model', '3889-XX (hereinafter referred to only as the tined lead or Model', '3889) with commercially-approved accessories. Either the InterStim', 'Tined Lead Model 3889 or the temporary Test Stimulation Lead (the', 'lead is sold via Models 305901, 305906 or 309101, hereinafter', 'referred to only as the Test Stimulation Lead) may be used for the', 'therapy evaluation.', 'In the rest of this document, \"advanced evaluation\" will refer to', 'therapy evaluation using InterStim Tined Lead and \"basic evaluation\"', 'will refer to therapy evaluation using temporary Test Stimulation', 'Lead.', 'Sponsor', 'Medtronic, Inc.', 'Indication under', 'The indication under investigation is overactive bladder (OAB).', 'investigation', 'There are no investigational devices used in this study, all study', 'products will be used in accordance with the product labeling.', 'Investigation Purpose', 'To assess the effect of three different amplitude settings (50% of', 'sensory threshold, 80% of sensory threshold and sensory threshold)', 'on urinary urge incontinence (UUI).', 'Sensory threshold is defined as the amplitude where the subject first', 'perceives the sensation of the stimulation in the perineum, perianal,', 'vaginal, or any location deemed appropriate by the investigator while', 'in a seated position.', 'Product Status', 'The InterStim II system is commercially approved for the treatment of', 'patients with OAB.', 'Primary Objective', 'To explore the effect of three different amplitude settings on urinary', 'urge incontinence (UUI).', 'Secondary Objective', 'To characterize results from the ICIQ-OABqol questionnaire for the', 'three different amplitude settings.', 'Additional Measures', 'to summarize safety', 'for the three different amplitude settings.', 'Study Design', 'This is a prospective, randomized, multicenter, single-blinded study to', 'explore the efficacy and quality of life (QoL) of 3 different amplitude', 'settings. The study will be conducted at approximately 20 centers in', 'the United States, Canada and Europe.', 'Enrolled subjects who meet all eligibility criteria, have successful', 'therapy evaluation (50% improvement in UUI or UF voiding', 'symptoms, or return to normal voiding of < 8 voids per day for UF', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 10 of 61', 'Medtronic', 'subjects) and qualify for a neurostimulator device implant in the study', 'will be randomized to one of the 3 amplitude settings. Subjects will', 'complete enrollment/baseline visits, lead implant, therapy evaluation,', 'neurostimulator device implant, randomization, 1-week follow-up', 'visit, 6-week follow-up visit and 12-week follow-up visit.', 'The total study duration for a subject is approximately 16 weeks.', 'Randomization', 'Subjects must meet all eligibility criteria and demonstrate a successful', 'therapy evaluation prior to being randomized to one of three therapy', 'amplitudes: sensory threshold, 50% of sensory threshold or 80% of', 'sensory threshold.', 'Sample Size', 'This study requires approximately 42 implanted and randomized', 'subjects with 12-week follow-up to be analyzed for the primary', 'objective. Approximately 60 subjects are estimated to be enrolled in', 'the study with approximately 48 randomized; however, these', 'numbers may vary to ensure that a minimum of 42 implanted', 'subjects complete the study.', 'Inclusion/Exclusion Criteria', 'Inclusion Criteria:', '1. Primary diagnosis of urinary urge incontinence (UUI) as', 'demonstrated on a 3-day baseline voiding diary', 'demonstrating at least 3 UUI episodes', '2. Female subjects 18 years of age or older', '3. Candidate for InterStim Lead Placement', '4.', 'Willing and able to accurately complete voiding diaries,', 'questionnaires, attend visits, and comply with the study', 'protocol (which includes maintenance of InterStim II', 'programming settings over the course of the study)', '5.', 'Willing and able to provide signed and dated informed', 'consent', '6.', 'Willing to maintain current regimen (dosage and frequency)', 'of any overactive bladder (OAB) medication', 'Exclusion Criteria:', '1. Have neurological conditions such as multiple sclerosis,', 'clinically significant peripheral neuropathy or spinal cord', 'injury', '2. History of diabetes unless the diabetes is well-controlled', 'through diet and/or medications', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']\n\n###\n\n", "completion": "END"}